title: Cereblon expression in multiple myeloma: not ready for prime time.
authors.affiliation: Haematology Laboratory, University Hospital, Nantes, France.
authors.forename: Laurence
authors.initials: L
authors.lastname: Lodé
authors.forename: Martine
authors.initials: M
authors.lastname: Amiot
authors.forename: Sophie
authors.initials: S
authors.lastname: Maiga
authors.forename: Cyrille
authors.initials: C
authors.lastname: Touzeau
authors.forename: Audrey
authors.initials: A
authors.lastname: Menard
authors.forename: Florence
authors.initials: F
authors.lastname: Magrangeas
authors.forename: Stephane
authors.initials: S
authors.lastname: Minvielle
authors.forename: Catherine
authors.initials: C
authors.lastname: Pellat-Deceunynck
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Bene
authors.forename: Philippe
authors.initials: P
authors.lastname: Moreau
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism*; D010447:Peptide Hydrolases / Q000096:biosynthesis*
chemical_list: D014408:Biomarkers, Tumor; D010447:Peptide Hydrolases
keywords: drug resistance; multiple myeloma; prognostic factors